• Contact
  • Press And News

Halitosis treatment with Kluyveromyces B0399

Trial 168: Halitosis treatment through the administration of antibiotic-resistant lactic yeast Kluyveromyces marxianus fragilis B0399 (K-B0399)

Cecchini F.1, Nobili A.2, Zanvit A. 3, Miclavez A.4, Nobili P. 3,5

1 Turval Laboratories Ltd, Udine, Italy.

2  Nobili Dental Office, Omegna (VB), Italy.

3 Biological Dentistry Department, Istituto Stomatologico Italiano; Milan, Italy.

4 Dental office; Udine, Italy.

5 Department of Surgical Sciences and Integrated Diagnostics, University of Genova; Italy.


The aim of this study is to measure the amount of VSC (Volatile Sulphur Compounds) and demonstrate the efficacy of probiotic therapy with follow-up at 7 and 14 days.

At the end of the treatment, about 91% of patients did not present halitosis.  Therefore results were achieved with a direct action on the intestine, not at an oral level.


This study proves that, besides the rebalancing effect of probiotics in dysbiosis, there are many immunological implications on GALT (Gut Associated Lymphoid Tissue).

Results show that the administration of K-B0399 enclosed in capsules has been proven effective in halitosis by acting at the intestinal microbiome level. 

Download the full paper
2024. © All rights reserved. Laboratori Turval Italia srl (TURVAL Laboratories Ltd.) - Head Office and Research Dpt: Friuli innovazione (AREA international Science Park-TS), Via Linussio 51-33100 Udine (IT) – P. IVA 01883020305
We use cookies to enhance your browsing experience. If you want to disable cookies, please set your browser.